Close Menu

NEW YORK – Investment bank JP Morgan has assigned an Overweight rating to the stocks of both Thermo Fisher Scientific and Qiagen a week after Thermo Fisher's planned acquisition of Qiagen fell through due to resistance from a substantial portion of Qiagen shareholders.

JP Morgan moved to an Overweight rating on both companies from a Not Rated designation assigned during a restriction period as the potential acquisition played out.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Pfizer and BioNTech announce they are seeking FDA authorization for their candidate SARS-CoV-2 vaccine.

Science has retracted a 2007 paper from a former Dutch minister and his colleagues, according to Retraction Watch.

The New York Times reports that a plan to cull minks in Denmark to prevent the spread of a new SARS-CoV-2 strain led to calls for the prime minister's resignation.

In Science this week: winner of the Science & SciLifeLab Prize for Young Scientists, and more.

Dec
01
Sponsored by
Roche

Management of viral infections is critical to prevent severe morbidities and consequences in immune-suppressed transplant patients.

Dec
03
Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion.